We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes.
- Authors
Vogel, Victor G.; Constantino, Joseph P.; Wickerham, D. Lawrence; Cronin, Walter M.; Cecchini, Reena S.; Atkins, James N.; Bevers, Therese B.; Fehrenbacher, Louis; Pajon Jr., Eduardo R.; Wade III, James L.; Robidoux, André; Margolese, Richard G.; James, Joan; Lippman, Scott M.; Runowicz, Carolyn D.; Ganz, Patricia A.; Reis, Steven E.; McCaskill-Stevens, Worta; Ford, Leslie G.; Jordan, V. Craig
- Abstract
The article discusses research on the risk of breast cancer and other disease outcomes, and the use of tamoxifen and raloxifene in North America. Research methods for the NSABP study or STAR P-2 Trial include characteristics of the postmenopausal women and biased-coin minimization algorithm. Both drugs are equally effective in reducing the risk of invasive breast cancer; however, raloxifene has a lower risk of thromboembolism and cataracts, and a higher risk of noninvasive breast cancer. Topics include uterine cancer, uterine hyperplasia, ischemic heart disease, fractures, stroke, and deaths among study participants.
- Subjects
NORTH America; BREAST cancer risk factors; TAMOXIFEN; RALOXIFENE; DISEASES in women; RESEARCH methodology; HEALTH risk assessment; ETIOLOGY of diseases
- Publication
JAMA: Journal of the American Medical Association, 2006, Vol 295, Issue 23, p2727
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.295.23.joc60074